INTRODUCTION {#s1}
============

Multiple myeloma (MM) is considered a malignancy of postgerminal center long-lived plasma cells. Although rare, T-cell--independent antigen stimulation can occur in these patients, and when it does, it results in the production of immunoglobulin M (IgM)--secreting short-lived plasma cells and lymphoplasmacytes. IgM MM is an infrequent subtype of MM, with an estimated prevalence of 0.5%.^[@B1]^ Because of its rarity and similarity to Waldenström macroglobulinemia (WM), little is known about its clinical characteristics, genetics, and prognosis compared with WM and other MM subtypes.

The presence of serum monoclonal IgM and uncontrolled plasma cell proliferation is associated with both IgM MM and WM. In most cases, it is not difficult to clinically differentiate between these two diseases. WM is suspected in patients with lymphadenopathy, hepatosplenomegaly, hyperviscosity syndrome, and the presence of a monoclonal IgM in the serum.^[@B2]^ A panel of B-cell antigens (CD19, CD20, CD21, CD22, and CD24) is present on the WM cells, whereas the CD23 antigen is usually absent.^[@B3]^ The concentration of IgM varies widely in WM, and it is not possible to define a concentration that reliably distinguishes WM from other lymphoproliferative disorders.^[@B4]^ Alternatively, IgM MM is suspected in the presence of osteolytic lesions, bone pain, monoclonal protein in blood or urine, or immune paresis, and it is confirmed with a bone marrow biopsy along with the other established International Myeloma Working Group (IMWG) criteria.^[@B5]^ Patients with IgM MM tend to have plasmacytic differentiation with high expression of CD138 and cytoplasmic immunoglobulin.^[@B6]^ However, when patients present with IgM monoclonal gammopathy, osteolytic lesions, and lymphadenopathies or hepatosplenomegaly, untangling the MM-WM differential diagnosis can be challenging.^[@B5]^

One of the characteristics of MM is the rearrangement of its immunoglobulin heavy and light chain genes. The high load of somatic hypermutations in the immunoglobulin heavy chain (*IgH*) locus is consistent with its postgerminal antigen-driven B-cell origin.^[@B7]^ There are five main translocation chromosomes in MM, which seem to be mediated mostly by errors in the IgH switch recombination that occurs during B-cell maturation in germinal centers.^[@B8]^ Those translocations are t(4;14), t(6;14), t(11;14), t(14;16), and t(14;20), and they result in the overexpression of *MMSET* and *FGFR3*,^[@B9]^ *CCND3*,^[@B10]^ *CCND1*,^[@B9],[@B11]^ *MAF*,^[@B12]^ and *MAFB*, respectively.^[@B13]^ Those aberrant chromosomal translocations are one of the central molecular hallmarks of MM. Thus, translocations involving the 14q32 region, for example, might represent clear-cut differences between MM and WM, and may be of diagnostic value in difficult patients.^[@B14]^

MATERIALS AND METHODS {#s2}
=====================

Patients {#s3}
--------

Twenty-one patients diagnosed with IgM MM between 1993 and 2013 were identified in the University of Arkansas for Medical Sciences Myeloma Institute for Research and Therapy (MIRT) patient database. Patient data collected for this study included overall survival (OS), bone disease status (as defined by x-rays, positron emission tomography \[PET\] scans, and magnetic resonance imaging scans), gene expression profiles (GEPs), and laboratory values (hemoglobin, calcium, and creatinine).

To determine the potential impact of possessing the IgM MM subtype on the prognosis of these patients, the survival of 21 patients with IgM MM was retrospectively compared with a historical control group of 158 patients with WM seen by MIRT^[@B15]^ and a group of 84 patients with non-IgM MM matched by important prognostic clinical factors: age,^[@B16]^ albumin and β~2~-microglobulin,^[@B17]^ creatinine,^[@B18]^ light chain type, serum lactate dehydrogenase,^[@B19]^ and abnormal cytogenetics.^[@B20]^ All patients were treated around the same time at MIRT ([Table 1](#T1){ref-type="table"}).

###### 

Baseline Characteristics of Patients With IgM MM and Non-IgM MM
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A diagnosis of IgM MM was based on the morphologic and immunophenotypical findings of biopsy specimens, the presence of a monoclonal IgM, and the presence of typical clinical characteristics of MM (lytic bone lesions, hypercalcemia, renal failure), using IMWG criteria.^[@B5]^ In a similar fashion, the diagnosis of WM was based on the morphologic and immunophenotypical findings of biopsy specimens, the presence of a monoclonal IgM, and the presence of typical clinical characteristics of WM (hepatosplenomegaly, lymphadenopathy). However, the presence of bone disease per se was not exclusive to the MM diagnosis because verified patients with WM have been described with pathologically confirmed bone involvement.^[@B21]-[@B23]^

Statistical Analysis {#s4}
--------------------

Survival curves were estimated using the Kaplan-Meier method and compared using the log-rank test. Matching between IgM and non-IgM MM was performed using R software^[@B24]^ and the MatchIT package^[@B25]^ using "to the nearest" method, with a 1 to 4 ratio without replacement, taking into consideration the baseline characteristics listed in [Table 1](#T1){ref-type="table"}.

Patients with IgM MM, non-IgM MM, and WM with available GEPs from MIRT were compared. To find gene expressions that could best distinguish between WM and non-IgM MM diagnoses, we selected the top 1,000 probe sets that maximized their gene-specific ratio between these two groups to within-groups sums of squares on the basis of the method by Dudoit et al.^[@B26]^ Next, we performed unsupervised hierarchical clustering on all samples, including patients with IgM MM using the top 1,000 probe sets.

For better illustration of the results, we reduced the dimensionality of the top 1,000 probe sets in WM and non-IgM MM groups to three dimensions using principal component analysis^[@B27]^ and partial least squares.^[@B28]^ Then, a linear support vector machine model^[@B29]^ was applied on the WM and non-IgM MM groups, and the boundary plane was plotted. Next, the same transformation was applied to IgM MM samples and added to the corresponding three-dimensional plot. The Database for Annotation, Visualization, and Integrated Discovery (DAVID)^[@B30]^ was used for the functional enrichment analysis.

RESULTS {#s5}
=======

Patient Characteristics and Survival {#s6}
------------------------------------

Of the 21 confirmed patients with IgM MM, 13 presented at MIRT for initial diagnosis, whereas eight were diagnosed and treated elsewhere before seeking care at MIRT. Seven patients presented with each of stages I, II, and III of the international staging system for plasma cell myeloma.^[@B31]^ Osteolytic bone lesions and/or pathologic fractures were evident by x-ray and computed tomography scan in 15 patients. Either magnetic resonance imaging or PET scan detected active bone focal lesions in three patients. Bone lesions were not observed in the remaining three patients. There was no organomegaly evident in patients with an available PET/computed tomography scan at baseline, and only one patient had evidence of hilar and mediastinal lymphadenopathy along with calcified lung nodules. Elevated creatinine levels (\> 2.0 mg/dL) were evident in four patients at the time of initial diagnosis. Disease characteristics of these patients and the WM and non-IgM MM control groups are listed in [Table 1](#T1){ref-type="table"}.

When the OS of the IgM MM group (4.9 years; 95% CI, 3.5 to ∞) was compared with a matched group of 84 patients with non-IgM MM (7.9 years; 95% CI, 5.3 to 10.75), no statistically significant difference was observed (*P* = .751; [Fig 1](#F1){ref-type="fig"}). Both groups had lower OS than the median OS of the historical group of 158 symptomatic patients with WM (9.2 years).^[@B15]^ As previously reported, the median OS of the WM group remained largely unaffected, even when the subgroup of patients with WM requiring treatment was analyzed (9.0 years).

![Kaplan-Meier estimates of overall survival in immunoglobulin M (IgM) multiple myeloma (MM; n = 21, red line) and a matched cohort of non-IgM MM (n = 84, blue line). No statistical difference was found for overall survival between these two groups, with a log-rank *P* equal to .751.](JGO.2016.008003f1){#F1}

Bone Marrow Karyotype, Fluorescence In Situ Hybridization, and DNA Flow Cytometry {#s7}
---------------------------------------------------------------------------------

In our cohort, baseline bone marrow cytogenetic data were available for 19 of 21 patients. Six of 19 patients had abnormal cytogenetics at presentation. Two of six patients had a t(11;14) translocation, one had t(14;16), and the other three had complex karyotype with hypodiploidy.

Only one patient who had interphase fluorescence in situ hybridization performed on bone marrow aspirate at baseline demonstrated t(11;14) translocation (CCND1/IgH) and a loss of chromosome 13; conventional cytogenetics for this patient was reported as normal.

Aneuploidy by DNA flow cytometry was evident in 13 of 21 patients (62%). This fact is in accordance with the already published data stating the frequency of aneuploidy in MM^[@B32]^ and is in striking antithesis with WM (aneuploidy was detected in 12 of 168 patients with DNA flow cytometry; unpublished data; *P* \< .001)

Gene Expression Profiling {#s8}
-------------------------

Of 21 patients with IgM MM, 12 had available GEP data on initial diagnosis. One patient had an upregulated *CCND2*.^[@B33]^ In six of these patients (50%), cyclin D1 gene expression was high. This is consistent with previously published data.^[@B34]^

To discover the features of gene expression that may be unique to IgM MM, we performed an unsupervised hierarchical cluster analyses of GEP of CD138-positive cells from the following samples: bone marrow aspirates of non-IgM MM and bone marrow aspirates of WM. Next, we added in the GEP data from bone marrow aspirates of the 21 patients with IgM MM.

A comparative genomic analysis was performed on the patients with IgM MM, non-IgM MM, and WM with available GEP data at initial diagnosis (12, 60, and 52 patients, respectively). We identified the best 1,000 probe sets (Data Supplement) that distinguish between WM and non-IgM MM. Many of these probes are for membrane proteins, such as CD19, CD20, CD22, CD24, CD138, components of the major histocompatibility complex, and adherence junctions.

Using support vector machine analysis alone^[@B29]^ or together with principal component analysis^[@B27]^ or partial least squares,^[@B28]^ [Figures 2](#F2){ref-type="fig"} and [3](#F3){ref-type="fig"} demonstrate that the majority of the IgM MM samples are on the non-IgM MM side of the boundary, indicating that the GEP of IGM MM is more closely related to non-IgM MM than it is to WM.

![Complete-linkage clustering analysis of Euclidean distance. Unsupervised hierarchical clustering was performed on all samples, including Waldenström macroglobulinemia (WM; green), immunoglobulin M (IgM) multiple myeloma (MM; red), and non-IgM MM (blue) gene expression profiles, using the 1,000 probesets retrieved in the filtering step.](JGO.2016.008003f2){#F2}

![Analysis of gene expression profiles (GEPs). (A) Principal components analysis of GEPs from immunoglobulin M (IgM) multiple myeloma (MM; red), non-IgM MM (blue), and patients with Waldenström macroglobulinemia (WM; green). (B) Partial least squares analysis of GEPs from IgM MM, non-IgM MM, and WM patients. Both methods were used to reduce the dimensionality of the top 1,000 probesets in WM and non-IgM MM groups to three dimensions. The same transformation was applied to IgM MM samples. Then, a linear support vector machine model was applied to the WM non-IgM MM groups, and the boundary plane was plotted. This method reflects the same results as the hierarchical clustering analysis ([Fig 2](#F2){ref-type="fig"}), in that the majority of the IgM MM samples (red) are on the non-IgM MM side of the boundary, indicating that the GEP of IGM MM is more closely related to non-IgM MM subtypes than it is to WM.](JGO.2016.008003f3){#F3}

Clinical Practice Points {#s10}
------------------------

-   MM and WM are plasma cell--related disorders.

-   WM and IgM myeloma present with elevated IgM levels. However, both disorders are clearly distinct by expression of Myd88 in WM and in terms of molecular profile, clinical presentation, treatment, and prognosis.

-   In the setting of elevated IgM levels, the presence of bone lytic lesions, hypercalcemia, and renal failure points toward IgM myeloma, whereas the presence of splenomegaly and lymphadenopathy points toward WM.

-   Our study demonstrates the difference between both diseases at the gene expression profiling level and provides a useful tool when differentiating both diseases is challenging.

DISCUSSION {#s9}
==========

IgM MM is a discrete clinical entity that should be distinguished from WM because their prognoses and treatments differ greatly. Using one of the largest series of patients with IgM MM ever published, we have shown that patients with IgM MM have a clinical presentation, prognosis, and GEP similar to patients with non-IgM MM.

Bone disease is associated with approximately 79% of newly diagnosed patients with MM when observed with conventional radiologic techniques.^[@B1]^ In our cohort of patients with IgM MM, bone disease was evident in the majority of patients, especially when specialized radiologic techniques were incorporated into the initial work-up.

Organomegaly is one of the clinical findings that is usually associated with WM or plasma cell leukemia.^[@B35]^ Avet-Loiseau et al^[@B14]^ reported two of eight patients with IgM MM with organomegaly; however, our results were consistent with the findings of Schuster et al,^[@B36]^ in that none of our patients presented with organomegaly or plasma cell leukemia.

To determine whether patients with IgM MM have a different prognosis than patients with non-IgM MM, OS for these two groups was compared using the Kaplan-Meier log-rank test. Patients with IgM MM displayed a median OS of 4.9 years, similar to patients with non-IgM MM receiving similar treatments at our institution (*P* \< .05). Patients with WM treated at our institution alternatively reported a longer median OS of 9 years.^[@B15]^

Previous studies^[@B16],[@B37],[@B38]^ have estimated that approximately 14% to 17% of patients with monoclonal gammopathy of undetermined significance (MGUS)--IgM type will develop a group of malignant lymphoid disorders, including non-Hodgkin lymphomas, chronic lymphocytic leukemia, and primary amyloidosis, within an average period of 4 years.

The observation of MGUS progressing to IgM MM is rarely reported. In one of those studies, Kyle et al^[@B16]^ reported an association between IgM MGUS and smoldering IgM MM in one patient of 213, and that patient exhibited biclonal gammopathy (IgM 386 mg/dL plus IgA λ 2840 mg/dL). Similarly, in our study, one of 21 patients presented with MGUS and progressed to IgM MM.

In general, genetic abnormalities are found in one third of patients with MM by conventional cytogenetics.^[@B39]^ Approximately 31% of our patients had cytogenetic abnormalities, three of whom had a t(11;14) or t(14;16) translocation, and both of these translocations are typically found in patients with MM.^[@B8]^

In concordance with the previous pathologic and clinical findings, GEPs for non-IgM MM and patients with WM were separated into two distinct clusters. Using these two groups as references, we added in the GEP data for patients with IgM MM. Clearly, both GEP data for IgM MM and patients with non-IgM MM clustered together, indicating that IgM MM is correctly classified as a subtype of MM, sharing the same genetic and pathologic characteristics. Only two of the 12 IgM MM samples (IgM MM-2 and IgM MM-6; [Table 2](#T2){ref-type="table"}) were located in the WM cluster ([Fig 2](#F2){ref-type="fig"}), whereas the remaining 10 IgM MM samples were located in the non-IgM MM cluster.

###### 

Predicted Probability of Group Membership for 12 IgM MM Patients Using SVM Together With PCA or PLS, or by Itself
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Although these two patients fulfilled the newest IMWG diagnostic criteria for MM,^[@B5]^ it should be noted that both patients did not clinically resemble typical MM. Both patients had mild to moderate plasma cell infiltration with absent or borderline immunoparesis and absent bone focal lesions by any imaging technique. Furthermore, in one of these two patients, renal insufficiency was due to light chain deposition disease without any evidence of cast nephropathy. In the other patient, bone disease was due to profound osteoporosis and associated pathologic fractures without any evidence of direct plasma cell involvement in pathology or imaging.

In conclusion, patients with IgM MM share clinical and genetic characteristics with the other subtypes of MM and have distinct differences from WM clinically, genetically, and in terms of prognosis. The IgM subtype of MM per se does not affect prognosis. All MM subtypes are affected by the established prognostic factors of MM, but the IgM subtype alone does not confer any additional prognostic indicator. In view of the remarkable differences in both treatment and prognosis between IgM MM and WM, an accurate diagnosis is essential and should be obtained with all available clinical, pathologic, and genetic assays.
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